Lyra Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Lyra Therapeutics (NASDAQ:LYRA) First Quarter 2023 Results
Key Financial Results
Net loss: US$16.3m (loss widened by 37% from 1Q 2022).
US$0.44 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Lyra Therapeutics Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 157%. Earnings per share (EPS) missed analyst estimates by 21%.
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are up 1.9% from a week ago.
Risk Analysis
It is worth noting though that we have found 4 warning signs for Lyra Therapeutics that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
